Arcus Biosciences Q3 revenue rises to $48 million; net loss widens to $92 million
Arcus Biosciences reported third-quarter 2024 revenue of $48 million, up from $32 million a year earlier, but its net loss widened to $92 million from $71 million as research and development spending rose to $123 million. The company said its $1.1 billion in cash, cash equivalents and marketable securities should fund operations into mid-2027, and it expects year-end 2024 cash of $950 million to $985 million.
Key points
- Q3 2024 revenue was $48 million versus $32 million in Q3 2023; nine-month revenue was $232 million versus $86 million.
- Q3 2024 net loss was $92 million, or $1.00 per share, compared with $71 million, or $0.94 per share, a year earlier.
- R&D expenses were $123 million in Q3 2024 versus $82 million, driven by late-stage clinical trial and headcount costs.
- Cash, cash equivalents and marketable securities were $1.1 billion at September 30, 2024, up from $866 million at December 31, 2023.
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.